

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 August 2023 (17.08.2023)



(10) International Publication Number
WO 2023/154519 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 417/14 (2006.01)
C07C 301/00 (2006.01) C07D 471/04 (2006.01)
C07D 207/34 (2006.01) C07D 487/04 (2006.01)
C07D 213/56 (2006.01) C07D 487/10 (2006.01)
C07D 213/61 (2006.01) C07D 491/048 (2006.01)
C07D 231/14 (2006.01) C07D 491/08 (2006.01)
C07D 233/32 (2006.01) C07D 491/107 (2006.01)
C07D 233/90 (2006.01) C07D 495/04 (2006.01)
C07D 235/26 (2006.01) C07F 7/08 (2006.01)
C07D 307/68 (2006.01) A61K 31/4164 (2006.01)
C07D 307/79 (2006.01) A61K 31/40 (2006.01)
C07D 333/38 (2006.01) A61K 31/415 (2006.01)
C07D 333/70 (2006.01) A61K 31/341 (2006.01)
C07D 401/04 (2006.01) A61K 31/381 (2006.01)
C07D 401/10 (2006.01) A61K 31/4436 (2006.01)
C07D 401/12 (2006.01) A61K 31/506 (2006.01)
C07D 401/14 (2006.01) A61K 31/5355 (2006.01)
C07D 403/04 (2006.01) A61K 31/4439 (2006.01)
C07D 403/14 (2006.01) A61K 31/444 (2006.01)
C07D 405/04 (2006.01) A61K 31/496 (2006.01)
C07D 405/14 (2006.01) A61K 31/4545 (2006.01)
C07D 409/04 (2006.01) A61K 31/437 (2006.01)
C07D 409/06 (2006.01) A61K 31/4985 (2006.01)
C07D 409/12 (2006.01) A61K 31/4365 (2006.01)
C07D 409/14 (2006.01) A61K 31/5025 (2006.01)
C07D 413/12 (2006.01) A61K 31/66 (2006.01)
C07D 413/14 (2006.01) A61K 31/695 (2006.01)
C07D 417/04 (2006.01)

(21) International Application Number:
PCT/US2023/012929

(22) International Filing Date:
13 February 2023 (13.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/309,917 14 February 2022 (14.02.2022) US

(71) Applicant: ACCENT THERAPEUTICS, INC. [US/US];
65 Hayden Avenue, Lexington, MA 02421 (US).

(72) Inventors: DANIELS, Matthew H.; c/o Accent Therapeu-
tics, Inc., 65 Hayden Avenue, Lexington, MA 02421 (US).


DUNCAN, Kenneth W.; c/o Accent Therapeutics, Inc., 65
Hayden Avenue, Lexington, MA 02421 (US). SPARLING,
Brian Andrew; c/o Accent Therapeutics, Inc., 65 Hayden
Avenue, Lexington, MA 02421 (US). LEE, Young-tae; c/o
Accent Therapeutics, Inc., 65 Hayden Avenue, Lexington,
MA 02421 (US). CASTRO, Jennifer; c/o Accent Thera-
peutics, Inc., 65 Hayden Avenue, Lexington, MA 02421
(US). RIBICH, Scott; c/o Accent Therapeutics, Inc., 65
Hayden Avenue, Lexington, MA 02421 (US). SICKMIER,
Ernest Allen; c/o Accent Therapeutics, Inc., 65 Hayden
Avenue, Lexington, MA 02421 (US). TASKER, Andrew
Stewart; c/o Accent Therapeutics, Inc., 65 Hayden Ave-
nue, Lexington, MA 02421 (US). MILLS, James Edward
John; c/o Accent Therapeutics, Inc., 65 Hayden Avenue,
Lexington, MA 02421 (US). WHITLOCK, Gavin; c/o Ac-
cent Therapeutics, Inc., 65 Hayden Avenue, Lexington, MA
02421 (US). JENNINGS, Andrew, J.; C/o Accent Ther-
apeutics, Inc., 65 Hayden Avenue, Lexington, MA 02421
(US).

(74) Agent: ZHANG, Xin et al.; McCarter & English, LLP, 265
Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF



(57) Abstract: Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

WO 2023/154519 A1

[Continued on next page]

Published:

— *with international search report (Art. 21(3))*